Skip to main content

Table 2 Acquisition rates of CRPA, CRAB, and CRE in clinical specimens between the intervention and control periods

From: Active surveillance testing to reduce transmission of carbapenem-resistant, gram-negative bacteria in intensive care units: a pragmatic, randomized cross-over trial

Ā 

Intervention period,

per 1000 person-days (95% CI)

Control period,

per 1000 person-days (95% CI)

Incidence rate ratio (95% CI)

P value

Modified intention-to-treat analysisa

Total

1.75 (0.87ā€“3.13)

3.33 (2.16ā€“4.92)

0.53 (0.23ā€“1.11)

0.07

CRPA

0.32 (0.04ā€“1.15)

1.07 (0.46ā€“2.10)

0.30 (0.03ā€“1.50)

0.10

CRAB

0.80 (0.26ā€“1.86)

1.73 (0.92ā€“2.96)

0.46 (0.13ā€“1.37)

0.13

CRE

0.80 (0.26ā€“1.86)

0.93 (0.38ā€“1.92)

0.85 (0.21ā€“3.12)

0.79

  1. CRPA carbapenem-resistant P. aeruginosa; CRAB carbapenem-resistant A. baumannii; CRE carbapenem-resistant Enterobacterales; CI confidence interval
  2. aExcluding SICU2 in both periods 1 and 2